home / stock / achv / achv news

ACHV News and Press, Achieve Life Sciences Inc. From 10/31/22

Stock Information
Company Name: Achieve Life Sciences Inc.
Stock Symbol: ACHV
Market: NASDAQ
Website: achievelifesciences.com
Menu
ACHV ACHV Quote ACHV Short ACHV News ACHV Articles ACHV Message Board
Get ACHV Alerts

News, Short Squeeze, Breakout and More Instantly...
ACHV - Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022

SEATTLE, Wash and VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine depende...
ACHV - Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

SEATTLE, Wash and VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addict...

ACHV - Achieve Life Sciences Announces Participation at Fall Investor Conferences

SEATTLE and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today...

ACHV - Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2022 Results - Earnings Call Transcript

Achieve Life Sciences, Inc. (ACHV) Q2 2022 Earnings Conference Call August 11, 2022 16:30 ET Company Participants Cindy Jacobs - President, Chief Medical Officer & Director Jerry Wan - Principal Accounting Officer John Bencich - Chief Executive Officer ...
ACHV - Achieve Life Sciences GAAP EPS of -$1.08 misses by $0.25

Achieve Life Sciences press release ( NASDAQ: ACHV ): Q2 GAAP EPS of -$1.08 misses by $0.25 . As of June 30, 2022, the company’s cash, cash equivalents, and restricted cash were $29.4 million. For further details see: Achieve Life Sciences GAAP EPS of ...

ACHV - Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update

SEATTLE and VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today ...

ACHV - Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022

SEATTLE and VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today ...
ACHV - Achieve Life Sciences Announces Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, July 01, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced...

ACHV - Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

Achieve Life Sciences ( NASDAQ: ACHV ) said it had begun screening subjects in a Phase 2 clinical trial for nicotine e-cigarette cessation. The mid-stage trial, dubbed ORCA-V1, will evaluate the efficacy and safety of 3mg cytisinicline dosed 3 times daily vs. plac...

ACHV - Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation

SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced...
Previous 10 Next 10